These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2609144)

  • 21. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term low dose carbimazole as a treatment for thyrotoxicosis. A report of ten cases with a review of the literature.
    Morgan GJ; Mayberry JF; Swithinbank JM
    Br J Clin Pract; 1984 Jun; 38(6):226-8. PubMed ID: 6547616
    [No Abstract]   [Full Text] [Related]  

  • 23. [Results of thyrostatic therapy of hyperthyroidism in patients with Basedow's disease and disseminated autonomy].
    Meng W; Meng S; Hampel R; Ventz M; Männchen E; Weber W; Streckenbach B
    Dtsch Z Verdau Stoffwechselkr; 1987; 47(6):337-40. PubMed ID: 3129277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
    Charreire J; Karsenty G; Bouchard P; Schaison G
    Clin Exp Immunol; 1984 Sep; 57(3):633-8. PubMed ID: 6147216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse.
    Weetman AP; Pickerill AP; Watson P; Chatterjee VK; Edwards OM
    Q J Med; 1994 Jun; 87(6):337-41. PubMed ID: 7913766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F; González-Ortiz M; Durón H; Sánchez C
    Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.
    Clerc J; Izembart M; Dagousset F; Jaïs JP; Heshmati HM; Chevalier A; Léger AF; Barritault L
    J Nucl Med; 1993 Mar; 34(3):387-93. PubMed ID: 8441028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperthyroidism in Graves' disease--antithyroid drug treatment].
    Schumm-Draeger PM
    Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():41-5. PubMed ID: 10355049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Unclear weight loss. Basedow's disease resp. Graves' disease].
    Stettler LB
    Praxis (Bern 1994); 2004 Oct; 93(42):1743-4. PubMed ID: 15529962
    [No Abstract]   [Full Text] [Related]  

  • 32. [Dynamic thyroid hormone levels during the thyrostatic treatment of Basedow's disease].
    Vŭrbanov V; Zakharieva B; Manolov D
    Vutr Boles; 1988; 27(4):15-8. PubMed ID: 2463711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy].
    Allannic H; Lorcy Y; Leguerrier AM; Delambre C; Stetieh H; Madec AM; Orgiazzi J
    Presse Med; 1991 Apr; 20(14):645-6, 649-51. PubMed ID: 1710802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for carbimazole as an antioxidant?
    Wilson R; Buchanan L; Fraser WD; Jenkins C; Smith WE; Reglinski J; Thomson JA; McKillop JH
    Autoimmunity; 1998; 27(3):149-53. PubMed ID: 9609132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Accidents attributable to carbimazole in the treatment of Basedow's disease].
    Le Guerrier AM; Lorcy Y; Allannic H
    Ann Endocrinol (Paris); 1984; 45(6):381-5. PubMed ID: 6549531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-triiodothyronine antibodies in Basedow's disease treated with carbimazole].
    Heshmati HM; Izembart M; Turpin G; Vallée G
    Presse Med; 1989 Dec 16-23; 18(42):2066. PubMed ID: 2532348
    [No Abstract]   [Full Text] [Related]  

  • 37. Relapse after short-term antithyroid therapy of Graves' disease.
    Burr WA; Fitzgerald MG; Hoffenberg R
    N Engl J Med; 1979 Jan; 300(4):200. PubMed ID: 581607
    [No Abstract]   [Full Text] [Related]  

  • 38. [Results of the surgical treatment of Basedow's disease. Apropos of 30 cases].
    Abdelmoumene N; Maoui R; El Okby A; Benmiloud M
    Ann Endocrinol (Paris); 1982; 43(3):193-202. PubMed ID: 6818892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose.
    Edmonds CJ; Tellez M
    Eur J Endocrinol; 1994 Aug; 131(2):120-4. PubMed ID: 8075780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of long-term antithyroid treatment of graves' disease in relation to iodine intake.
    Lumholtz IB; Poulsen DL; Siersbaek-Nielsen K; Friis T; Rogowski P; Kirkegaard C; Hansen JM
    Acta Endocrinol (Copenh); 1977 Mar; 84(3):538-41. PubMed ID: 576529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.